An Open-Label Extended-Use Study of Oral CEP-701 in Patients With Hematologic Malignancies Who Have Participated in a Clinical Study of CEP-701

Cephalon Inc.0 个研究点目标入组 100 人开始时间: 2008年3月20日最近更新: 2012年5月1日

适应症

试验速览

暂无简介。

•- Patients meets 1 of the following criteria:
•>Participation in a previous clinical study of oral CEP 701 and would benefit by continuing treatment with CEP 701.
•>Patients randomized to chemotherapy alone in study C0701a/204/ON/US may also be included in this study if in the opinion of their physician they might benefit by receiving oral CEP-701, and they are withdrawn from C0701a/204/ON/US for additional chemotherapy or haematopoietic stem cell transplantation.
•- Aged 18 years or older.
•- Written informed consent is obtained.
•- Diagnosis of hematologic malignancy.
•- Patient must be willing and able to comply with study restrictions and to return to the clinic for clinical and follow up evaluations as specified in this protocol.
•- Enter this study within 30 days after participating in the previous clinical study of oral CEP 701; or, if the patient received chemotherapy after the previous study of oral CEP 701, within an interval of 3 to14 days after receiving the final dose of chemotherapy.
•- Women must be neither pregnant or lactating, and either not of child-bearing potential or using adequate contraception with a negative pregnancy test result at study entry.
•Are the trial subjects under 18? no
•Number of subjects for this age range:
•F.1.2 Adults (18-64 years) yes
•F.1.2.1 Number of subjects for this age range
•F.1.3 Elderly (>=65 years) yes
•F.1.3.1 Number of subjects for this age range

•- Active gastrointestinal ulceration or bleeding.
•- 1 or more of the following abnormal clinical chemistry laboratory values:
•->bilirubin is more than 2 times the upper limit of normal (ULN)
•->alanine aminotransferase (ALT) or aspartate aminotransferase (AST) is more than 3 times ULN
•- Serum creatinine is more than 2.0 mg/dl
•- The patient requires current treatment for the human immunodeficiency virus (HIV) with protease inhibitors or requires potent CYP3A4 inhibitors including cyclosporine, clotrimazole, fluconazole, itraconazole, voriconazole, ketoconazole, erythromycin, clarithromycin, troleandomycin, and nefazodone

发起方